Screening of FDA approved drugs against SARS-CoV-2 main protease: coronavirus disease (2021)
Balakrishnan, Vijayakumar 
; Lakshminarayanan, Karthik
Source: International Journal of Peptide Research and Therapeutics. Unidade: IFSC
Subjects: CORONAVIRUS, FÁRMACOS, CÉLULAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BALAKRISHNAN, Vijayakumar e LAKSHMINARAYANAN, Karthik. Screening of FDA approved drugs against SARS-CoV-2 main protease: coronavirus disease. International Journal of Peptide Research and Therapeutics, v. 27, n. 1, p. 651-658, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10989-020-10115-6. Acesso em: 14 nov. 2024.APA
Balakrishnan, V., & Lakshminarayanan, K. (2021). Screening of FDA approved drugs against SARS-CoV-2 main protease: coronavirus disease. International Journal of Peptide Research and Therapeutics, 27( 1), 651-658. doi:10.1007/s10989-020-10115-6NLM
Balakrishnan V, Lakshminarayanan K. Screening of FDA approved drugs against SARS-CoV-2 main protease: coronavirus disease [Internet]. International Journal of Peptide Research and Therapeutics. 2021 ; 27( 1): 651-658.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1007/s10989-020-10115-6Vancouver
Balakrishnan V, Lakshminarayanan K. Screening of FDA approved drugs against SARS-CoV-2 main protease: coronavirus disease [Internet]. International Journal of Peptide Research and Therapeutics. 2021 ; 27( 1): 651-658.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1007/s10989-020-10115-6
